Quality of Life After Radical Prostatectomy

Similar documents
Prostatectomy, pelvic lymphadenect. Med age 63 years Mean followup 53 months No other cancer related therapy before recurrence. Negative.

Beyond the PSA: Genomic Testing in Localized Prostate Cancer

7. Prostate cancer in PSA relapse

Thomas A. Kollmorgen, M.D. Oregon Urology Institute

Prostate Cancer Treatment Comparison

Prostate Cancer Treatment Comparison

SRO Tutorial: Prostate Cancer Treatment Options

Individual Prediction

Radiation Therapy for Prostate Cancer: Treatment options and future directions

The Business of Prostate Cancer Care: A Clinician-Researcher s Perspective

Does my patient need more therapy after prostate cancer surgery?

Cancer research in the Midland Region the prostate and bowel cancer projects

PSA Screening for Prostate Cancer Information for Care Providers

NERVE GRAFT TO RESTORE ERECTILE FUNCTION DURING RADICAL PROSTATECTOMY

Questions to ask my doctor: About prostate cancer

Questions to Ask My Doctor About Prostate Cancer

Prostate cancer. Christopher Eden. The Royal Surrey County Hospital, Guildford & The Hampshire Clinic, Old Basing.

Focal therapy for prostate cancer: seriously or seriously? Disclosures

Historical Basis for Concern

Local Salvage Therapies After Failed Radiation for Prostate Cancer. Biochemical Failure after Radiation

Proton Therapy for Prostate Cancer: Your Questions, Our Answers.

Prostate cancer is the most common cause of death from cancer in men over age 75. Prostate cancer is rarely found in men younger than 40.

Facing Prostate Cancer Surgery? Learn about minimally invasive da Vinci Surgery

Precise, Minimally Invasive Prostate Cancer Removal

Screening for Prostate Cancer

Prostate Cancer Screening: Are We There Yet? March 2010 Andrew M.D. Wolf, MD University of Virginia School of Medicine

PROSTATE CANCER. Get the facts, know your options. Samay Jain, MD, Assistant Professor,The University of Toledo Chief, Division of Urologic Oncology

TO SCREEN OR NOT TO SCREEN: THE PROSTATE CANCER

An Introduction to PROSTATE CANCER

855-DRSAMADI or

SIOG Guidelines Update 2014 Prostate Cancer. Dr Helen Boyle Centre Léon Bérard SIOG meeting 25 October 2014,Lisbon

The 4Kscore blood test for risk of aggressive prostate cancer

Robotic Assisted Laparoscopic Salvage Prostatectomy for Radiation Resistant Prostate Cancer

Issues Concerning Development of Products for Treatment of Non-Metastatic Castration- Resistant Prostate Cancer (NM-CRPC)

Survivorship Care Plans Guides for Living After Cancer Treatment

Carcinoma of the Cervix. Kathleen M. Schmeler, MD Associate Professor Department of Gynecologic Oncology

These rare variants often act aggressively and may respond differently to therapy than the more common prostate adenocarcinoma.

Update on Prostate Cancer: Screening, Diagnosis, and Treatment Making Sense of the Noise and Directions Forward

Brian Louis Cohen, M.D., M.P.H.

da Vinci Prostatectomy Information Guide (Robotically-Assisted Radical Prostatectomy)

CYBERKNIFE RADIOSURGERY FOR EARLY PROSTATE CANCER Rationale and Results. Alan Katz MD JD Flushing, NY USA

Breast Cancer Pathway

Treating Prostate Cancer

Prostate cancer is the second most

Detection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical

Advances in Diagnostic and Molecular Testing in Prostate Cancer

Integrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases

The PSA Controversy: Defining It, Discussing It, and Coping With It

Prostate Cancer 2014

Neoadjuvant and Adjuvant Hormone Therapy: How and When?

CMScript. Member of a medical scheme? Know your guaranteed benefits! Issue 7 of 2014

2010 SITE REPORT St. Joseph Hospital PROSTATE CANCER

Oncology Annual Report: Prostate Cancer 2005 Update By: John Konefal, MD, Radiation Oncology

ICHOM-INTERN L CONSORTIUM ON HEALTH OUTCOMES MEASUREMENT

PSA Testing 101. Stanley H. Weiss, MD. Professor, UMDNJ-New Jersey Medical School. Director & PI, Essex County Cancer Coalition. weiss@umdnj.

Re irradiation Using HDR Interstitial Brachytherapy for Locally Recurrent. Disclosure

Prostate Cancer Screening in Taiwan: a must

Clinical Trials and Radiation Treatment. Gerard Morton Odette Cancer Centre Sunnybrook Research Institute University of Toronto

The Science behind Proton Beam Therapy

American Urological Association (AUA) Guideline

Bridging Techniques. What s between EMR and Traditional Surgery? Elisabeth C. McLemore, MD, FACS, FASCRS

Understanding the. Controversies of. testosterone replacement. therapy in hypogonadal men with prostate cancer. controversies surrounding

Clinical Practice Assessment Robotic surgery

Recovery of Erectile Function After Radical Prostatectomy Vanderbilt University Department of Urologic Surgery

Prostate Cancer. Treatments as unique as you are

Prostate Cancer. There is no known association with an enlarged prostate or benign prostatic hyperplasia (BPH).

FAQ About Prostate Cancer Treatment and SpaceOAR System

Pancreatic Cancer: FDA Approved Treatments and Clinical Trials

PATIENT GUIDE. Localized Prostate Cancer

Long-acting testosterone injections for treatment of testosterone deficiency after brachytherapy for prostate cancer

Focus on PSA Screening for Prostate Cancer Vol. 28 Supplement, February Prostate Cancer: Should We Be Screening?

PSA screening in asymptomatic men the debate continues keyword: psa

Treatment and Surveillance of Non- Muscle Invasive Bladder Cancer

Transcription:

Quality of Life After Radical Prostatectomy Bernard H. Bochner, MD FACS Attending Surgeon, Urology Service Vice Chairman, Department of Surgery Memorial Sloan-Kettering Cancer Center

Quality of Life After Radical Prostatectomy Individual series data available HOWEVER: Poor characterization of patient groups (case mix) Variation in reporting method Different definitions for outcomes The lack of high quality evidence makes comparative evaluations between different treatments difficult No QOL data from randomized trials available

Health-Related Quality of Life Patient-centered variable taken from the field of health services research Can be measured reliably Questionnaires (instruments) are pilot-tested the validated Domains can be general or disease-specific Responses to items are scored and can be used to calculate a summary score for each domain

Patients; N=1201; Spouses, N=625 Treatment Modalities Radical Prostatectomy, N=603 Brachytherapy, N=306 External Beam Radiotherapy, N=292

Sexual function caused moderate or severe distress after 2 years: in 43% of men after RP, 37% after XRT and 30% after brachy; ED caused distress in 44%, 22% and 13% of partners. Urinary function lead to moderate or severe distress after 1 yr: in 7% of patients after RP, 18% after brachy, and 11% after XRT, and in 4-5% of partners. GI symptoms caused moderate or severe distress in 9% of patients (and 4-5% of partners) a year after radiation (brachy or XRT).

Figure 1. Changes in Quality of Life after Primary Treatment for Prostate Cancer.

Surgeon Factor: Outcomes after Radical Prostatectomy To what degree are the outcomes of radical prostatectomy perioperative complications, urinary incontinence, erectile dysfunction, surgical margins and long term cancer control related to surgical technique in addition to the characteristics of the patient and the cancer?

Variability in 5-yr progression-free probabilities among experienced surgeons (>40 cases) adjusted for case mix p<0.0005

Heterogeneity in outcome among surgeons at MSKCC: full continence (no pads) Bianco et al J Urol 2010

Heterogeneity in outcome among surgeons at MSKCC: full potency (+/- oral agents) Bianco et al J Urol 2010

Effect of Surgeon and Hospital Volumes For Radical Cystectomy Adjusted Mortality operative mortality is largely mediated by surgeon volume. Patients can often improve their chances of survival substantially by selecting surgeons who perform the operation frequently. Birkmeyer et al, NEJM, 2003

Surgeon and Impact On Outcome After RRP: High Volume Surgeons Outcomes (%) 35 30 25 20 15 10 5 Low Medium High Very high Surgeon Volume 0 Postoperative complications Late urinary complications Long-term incontinence Begg CB, Reidel ER, Bach PB, Kattan MW, Schrag D, WarrenJL, Scardino PT. Variations in morbidity after radical prostatectomy. NEJM 2002; 346:1142.

Surgeon and Impact On Outcome After RRP: Urinary Complications, High Volume Surgeons 35 30 25 20 15 10 5 0 0-4.9 5-9.9 10-14.9 15-19.9 20-24.5 25-29.9 Expected (n=159) 30-34.9 35-39.9 40-44.9 45-50 > 50 % Late Urinary Complications after RP (Bianco F et al. J Urol 2005)

Surgeon and Impact On Outcome After RRP: Urinary Complications, High Volume Surgeons 35 30 25 20 15 10 5 0 0-4.9 5-9.9 Expected 10-14.9 15-19.9 20-24.5 25-29.9 30-34.9 35-39.9 40-44.9 Observed p <.0001 % Late Urinary Complications after RP 45-50 > 50

Achieving Optimal Outcomes after Radical Prostatectomy: The Trifecta Optimal outcome after RP is cancer control with full recovery of continence and potency. Individual studies report rates of ED, incontinence or cancer recurrence (rising PSA) in isolation. These rates do not adequately reflect the quality of the surgery nor fully inform patients of the probability of being cured of cancer and recovering normal urinary and sexual function ( Trifecta ). Saranchuk J, J Clin Oncol 2005; 23:4146

Cummulative Incidence Probabilities of Event 0.0 0.2 0.4 0.6 0.8 Probability of recovering complete continence, normal erectile function and freedom from biochemical recurrence ( Trifecta ) after RP alone Trifecta Outcomes (Potent, Continent, PSA undetectable) Failure of RP to control prostate cancer N=647 Markov model 3 6 9 12 15 18 21 24 Time (Months) from Radical Prostatectomy Cumulative probability of continence, potency and freedom from biochemical recurrence Probability of PSA recurrence

Variation among surgeons in achieving optimal results (TRIFECTA) 0.80 0.85 0.90 0.95 1.00 0.0 0.2 0.4 0.6 0.8 1.0 Probability of being both potent and continent at 12 months

Cumulative Incidence of Recovery of Continence (No Pads or Leakage): Open vs. Lap RP Touijer A et al. J Urol 2008; 197:1811 Open Lap HR 0.56, p<.0005

QOL After Radical Prostatectomy Conclusion All treatments for prostate cancer adversely effect QOL Poor quality comparative data makes direct comparisons very difficult Surgical skill strongly associated with oncologic and functional outcomes after RRP Technology has not proven to provide major breakthrough in improved QOL over good open surgery.